Geron (GERN) Current Deferred Revenue (2010 - 2015)
Geron's (GERN) quarterly Current Deferred Revenue came in at $35.0 million in Q2 2015, little changed quarter-over-quarter from $35.0 million in Q1 2015.
Analysis
Geron (GERN) Current Deferred Revenue (2010 - 2015) Analysis & Trends
Geron has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $35.0 million for Q2 2015.
- In Q2 2015, Current Deferred Revenue changed N/A year-over-year to $35.0 million; the TTM figure through Jun 2015 stood at $35.0 million (changed N/A YoY), while the FY2014 annual figure was $35.0 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $35.0 million for Q2 2015 at Geron, roughly flat from $35.0 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $35.0 million in Q4 2014 to a low of $35.0 million in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2015 | 35.00 Mn |
| Mar 31, 2015 | 35.00 Mn |
| Dec 31, 2014 | 35.00 Mn |
| Dec 31, 2010 | 350,000.00 |